OPKO Health, Inc. Convertible Notes Payable, Noncurrent
OPKO Health, Inc. (OPK) had Convertible Notes Payable, Noncurrent of $89.86 million as of 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation › Long-Term Debt, Excluding Current Maturities › Notes Payable, Noncurrent
us-gaap:ConvertibleLongTermNotesPayable · last filed 2026-08-28
- 2026-06-30: Convertible Notes Payable, Noncurrent $89.86M.
- 2026-03-31: Convertible Notes Payable, Noncurrent $87.38M.
- 2025-12-31: Convertible Notes Payable, Noncurrent $85.02M.
- 2025-09-30: Convertible Notes Payable, Noncurrent $82.70M.
| Period end | Convertible Notes Payable, Noncurrent | Convertible Notes Payable, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $89.86M 10-Q/A · filed 2026-08-28 | |
| 2026-03-31 | $87.38M 10-Q/A · filed 2026-08-28 | |
| 2025-12-31 | $85.02M 10-Q/A · filed 2026-08-28 | |
| 2025-09-30 | $82.70M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $80.47M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $77.23M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $173.61M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $178.69M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $175.94M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $323.11M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $214.32M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $213.28M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $212.30M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $211.33M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $210.37M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $141.81M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $211.48M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $210.52M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $187.94M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $185.54M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $183.20M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $224.78M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $221.99M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $219.19M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $216.46M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $213.81M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $211.21M 10-K · filed 2021-02-18 | |
| 2019-09-30 | $208.69M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $206.16M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $203.71M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $57.30M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $56.60M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $55.89M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $55.20M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $29.16M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $28.59M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $34.76M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $39.28M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $43.70M 8-K · filed 2019-01-29 | |
| 2016-09-30 | $51.54M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $45.23M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $49.61M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $48.99M 10-K · filed 2017-03-01 | $49.41M 10-K · filed 2016-02-29 |
| 2015-09-30 | $44.21M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $109.20M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $106.67M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $131.45M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $114.88M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $116.36M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $224.80M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $211.91M 10-K · filed 2015-02-27 | |
| 2013-09-30 | $208.92M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $188.52M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $196.42M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $0.00 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |